Results 151 to 160 of about 86,839 (276)

Infection control in the brain and the eye

Acta Ophthalmologica, EarlyView.
Abstract The Central Nervous System (CNS), comprising the brain and the eye, is considered to have a ‘privileged’ mechanism for dealing with immunological challenge (immune privilege, IP). CNS IP has been revealed through experiments using foreign protein antigens and cell and tissue alloantigens (grafts), but evidence for a role for IP in modulating ...
John V. Forrester, Paul G. McMenamin, Samantha J. Dando   +2 more
wiley   +1 more source

Role of therapeutic plasma exchange in the management of COVID-19-induced cytokine storm syndrome. [PDF]

Transfus Apher Sci, 2022
Beraud M, Hashami SA, Lozano M, Bah A, Keith P.   +4 more
europepmc   +1 more source

The oscillatory response of the electroretinogram and neuronal adaptation

Acta Ophthalmologica, EarlyView.
Abstract After more than 50 years, there still remains a challenge and an interest to know more as well as extend and deepen our understanding of the small rapid wavelets, the oscillatory potentials (OPs), of the electroretinogram (ERG) and the neuronal adaptation of the retina.
Lillemor Wachtmeister, Anders Eklund
wiley   +1 more source

Mycobacterial Antigen Driven Activation of CD14++CD16- Monocytes Is a Predictor of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. [PDF]

, 2014
Anbalagan, S, Andrade, BB, Antonelli, LR, Barber, DL, Follmann, D, Jensen, SM, Meintjes, G, Narendran, G, Nayak, K, Porter, BO, Schechter, ME, Sereti, I, Sher, A, Singh, A, Subramanian, S, Swaminathan, S, van der Plas, H, Wilkinson, KA, Wilkinson, RJ   +18 more
core   +1 more source

Bioprospecting of microalgae metabolites against cytokine storm syndrome during COVID-19. [PDF]

Mol Biol Rep, 2022
Wan Afifudeen CL, Teh KY, Cha TS.
europepmc   +1 more source

Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes

Frontiers in Immunology
There is a continuous cycle of activation and contraction in the immune response against pathogens and other threats to human health in life. This intrinsic yin-yang of the immune response ensures that inflammatory processes can be appropriately controlled once that threat has been resolved, preventing unnecessary tissue and organ damage.
Amy Armstrong, Amy Armstrong, Yuting Tang, Neelam Mukherjee, Neelam Mukherjee, Nu Zhang, Gang Huang, Gang Huang, Gang Huang   +8 more
openaire   +3 more sources

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country

British Journal of Haematology, EarlyView.
The spectrum of Castleman diseases has expanded over the past three decades. The phenotype of the diseases varies not only among the three major types but also according to the patient ancestry. Summary Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time.
Eric Oksenhendler, Marion Malphettes, Véronique Meignin, David Boutboul, Lionel Galicier   +4 more
wiley   +1 more source

Intravenous anakinra for cytokine storm syndromes – Authors' reply [PDF]

The Lancet Rheumatology, 2020
Mehta, Puja, Cron, Randy Q, Hartwell, James, Manson, Jessica J, Tattersall, Rachel   +4 more
openaire   +2 more sources

Human brain matters: Navigating the neuropathology of COVID‐19

Brain Pathology, EarlyView.
Severe COVID‐19 is associated with vascular dysregulation and chronic neuroinflammation, leading to axonal injury and neurodegeneration. In long COVID or PASC, persistent alterations in neuroimaging and biofluid biomarkers reflect ongoing neuronal damage and neuroinflammation, contributing to long‐term neurological symptoms including fatigue, cognitive
Juliana M. Nieuwland, Angelica Scaramuzza, Marianna Bugiani, Wilma D. J. van de Berg, Jinte Middeldorp   +4 more
wiley   +1 more source

Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269

Cancer Science, EarlyView.
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka, Kyoko Kawasaki, Yoshiki Sumitomo, Masato Saito, Akari Yao, Munetoshi Ando   +5 more
wiley   +1 more source